Last reviewed · How we verify
NCT05161299: CovidSurg-3
CovidSurg-3: Outcomes of Surgery in COVID-19 Infection
trial testing Surgery (across all specialities) in SARS-CoV-2 Infection in 2,000 participants. Status unknown.
28 February 2022
Quick facts
| Lead sponsor | University of Birmingham |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 2,000 |
| Start date | 13 December 2021 |
| Primary completion | 28 February 2022 |
| Estimated completion | 29 March 2022 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Surgery (across all specialities)
Conditions studied
- SARS-CoV-2 Infection — all drugs for SARS-CoV-2 Infection →
- Surgery — all drugs for Surgery →
Sponsor
University of Birmingham
Who can join
Eligibility, any sex, with SARS-CoV-2 Infection or Surgery. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
COVID-19 has significant detrimental impacts on surgical systems and patient outcomes. CovidSurg has provided the best available evidence to guide delivery of safe surgery during the pandemic. However, CovidSurg data were collected in 2020 when the wildtype SARS-CoV-2 virus was dominant, and therefore there is a need to for renewed rapid data to guide global practice during Omicron COVID-19 waves. CovidSurg-3 is an extension to CovidSurg and was initiated in response to the emergence of the Omicron variant. CovidSurg-3 has two separate components: * Patient-level component: Collection of outcome data for patients with peri-operative SARS-CoV-2. * Hospital-level component: Collection of aggregated case-mix data. Hospitals in countries with low community SARS-CoV-2 infection rates can contribute towards this component.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
A prognostic model for use before elective surgery to estimate the risk of postoperative pulmonary complications (GSU-Pulmonary Score): a development and validation study in three international cohorts.
NIHR Global Health Research Unit on Global Surgery, STARSurg Collaborative. · · 2024 · cited 13× · PMID 38906616 · DOI 10.1016/s2589-7500(24)00065-7
Verify or expand the search:
- PubMed search for NCT05161299
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for SARS-CoV-2 Infection
Currently open trials in the same condition.
- NCT07079670 — Safety and Immunogenicity of NVX-CoV2705 · Phase 3 · active not recruiting
- NCT05697068 — Intervention to Prevent Household and Community Spread of COVID-19 Among Latinos · NA · active not recruiting
- NCT05172011 — Understanding the Long-term Impact of COVID on Children and Families · active not recruiting
- NCT05141058 — T Cell Therapy Opposing Novel COVID-19 Infection in Immunocompromised Patients · Phase 1 · recruiting
- NCT05046470 — SARS-CoV-2 Transmission in Belgian Primary Schools of the Federation Wallonia - Brussels: An Epidemiological Pilot Study · active not recruiting
Other University of Birmingham trials
Trials by the same sponsor.
- NCT07160686 — Apixaban to Prevent Venous Thromboembolism in Ambulatory Lung Cancer Patients Undergoing Systemic Anticancer Treatment · Phase 3 · not yet recruiting
- NCT07446166 — TETANUS Antibody Detection in Saliva Study · NA · not yet recruiting
- NCT07294794 — Personalised Pharmacometabolomic-guided Strategy Trial to Optimise Treatment for Hypertension · NA · not yet recruiting
- NCT07246356 — Feasibility and Efficacy of GTEP for Birth Trauma · NA · recruiting
- NCT06932653 — Reducing Deaths After Surgery in Low- and Middle-income Countries: A Pilot Cluster Randomised Trial · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05161299 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Birmingham
- Last refreshed: 17 December 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05161299.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing